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The p-i Concept: Pharmacological Interaction of Drugs
With Immune Receptors
Werner J. Pichler
Abstract: The immune response in drug hypersensitivity is normally
explained by the hapten hypothesis. It postulates that drugs with a
molecular weight of less than 1000D are too small to cause an immune
response per se. However, if a chemically reactive drug or drug
metabolite binds covalently to a protein and thus forms a so-called
hapten-carrier complex, this modiﬁed protein can induce an immune
response. This concept has recently been supplemented by the p-i
concept (or pharmacological interaction with immune receptors),
which postulates that some drugs that lack hapten characteristics can
bind directly and reversibly (noncovalently) to immune receptors and
thereby stimulate the cells. For example, a certain drug may bind to a
particular T-cell receptor, and this binding sufﬁces to stimulate the T
cell to secrete cytokines, to proliferate, and to exert cytotoxicity. The
p-i concept has major implications for our understanding of drug
interaction with the speciﬁc immune system and for drug hypersensi-
tivity reactions. It is based on extensive investigations of T-cell clones
reacting with the drug and recently of hybridoma cells transfected with
the drug-speciﬁc T-cell receptor for antigen (TCR). It is a highly
speciﬁc interaction dependent on the expression of a TCR into which
the drug can bind with sufﬁcient afﬁnity to cause signaling. Small
modiﬁcation of the drug structure may already abrogate reactivity.
Stimulation of T cells occurs within minutes as revealed by rapid Ca++
inﬂux after drug addition to drug-speciﬁc T-cell clones or hybridoma
cells, thus, before metabolism and processing can occur. As the
immune system can only react in an immunologic way, the symptoms
arising after drug stimulation of immune receptors imitate an immune
response after recognition of a peptide antigen, although it is actually
a pharmacological stimulation of some T cells via their TCRs.
Clinically, the p-i concept could explain the sometimes rapid
appearance of symptoms without previous sensitizations and the
sometimes chaotic immune reaction of drug hypersensitivity with
participation of different immune mechanisms while normal immune
reactions to antigens are highly coordinated. Nevertheless, because the
reactions lead to expansion of drug-reactive cells, many features such
as skin test reactivity and stronger reactivity upon reexposure are
identical to real immune reactions.
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In drug hypersensitivity, 2 extremely polymorphic systemsencounter each other. On one hand, modern chemistry, which
allows synthesis of an endless amount of drugs often designed
to ﬁt into and thus blocking receptors or enzymes and, on the
other hand, the speciﬁc immune system, which is composed of
T and B cells expressing greater than 109 different T- or B-cell
receptors for antigen (TCR, BCR). The enormous polymor-
phism of the immune system allows it to react to all kinds of
different antigens and even to antigens that will be created in
the future. It surely does also express receptors into which
some old or new drugs may ﬁt. On the other hand, it is an
immunologic dogma that small molecules do not stimulate the
immune system. However, is this so? Or are there exceptions
to this rule?
THE HAPTEN AND PROHAPTEN CONCEPT
An immune reaction starts by involvement of the innate
immune system. The antigen (bacterium, virus, etc) stimulates
the innate immune system via, for example, Toll-like receptors
(TLRs) on dendritic cells and thereby sets an initial alarm
signal. The activated dendritic cells function as antigen-
presenting cells (APCs) as they take up and process complex
antigens, which subsequently are presented as peptides to T
cells in a suitable environment, mainly the lymph nodes. The
ensuing immune response is variable and efﬁcient, as different
antigens such as soluble or cell-bound viral antigens elicit a
distinct immune response, capable of eliminating the infec-
tious agent.
Small lowYmolecular weight compounds (G1000 D) are
thought to be too small to elicit such an immune response per
se. Nevertheless, small compounds such as drugs or metal ions
were found to be able to trigger an immune response.1Y5 The
hapten (and prohapten) model was developed and is currently
the accepted explanation for these observations: Chemically
reactive, small compounds (haptens) bind to proteins or
peptides and modify them.4Y6 These haptens have thereby 2
essential features for inducing an immune response.
a) They may stimulate the innate immune system by
covalently binding to cellular proteins and thereby
transmit a danger signal, which results in stimulation of
cells of the innate immune system,7Y9 such as up-
regulation of CD40. Exceptionally, they may happen to
bind to TLR7 and TLR8 directly and thus stimulate
dendritic cells. This was shown for imiquimod.10
b) They may stimulate the speciﬁc immune system. By
forming hapten-carrier complexes, they form neoanti-
genic structures. This hapten-protein complex is pro-
cessed and presented as hapten-modiﬁed peptide to T
cells, which can react with it.1Y4,11 Modiﬁed proteins
REVIEW ARTICLE
96 WAO Journal & June 2008
Received for publication December 31, 2007; accepted March 7, 2008.
From the Division of Allergology, Clinic for Rheumatology and Clinical
Immunology/Allergology, University of Berne, Berne, Switzerland.
Reprints: Werner J. Pichler, Division of Allergology, Clinic for Rheumatology
and Clinical Immunology/Allergology, PKT2 D572, Inselspital, CH-3010
Berne, Switzerland. E-mail: werner.pichler@insel.ch
Copyright * 2008 by World Allergy Organization
can also be immunogenic for B cells and thus elicit a
humoral immune response. This hapten modiﬁcation
can occur with soluble proteins, cell-bound proteins,
or with the major histocompatibility complex (MHC)Y
peptide complexes themselves, leading to distinct im-
mune responses (Fig. 1).1,3
Prohaptens are per se not chemically reactive and thus
unable to form a covalent bridge to peptides. To become
chemically reactive, they ﬁrst need to be converted into a
hapten by being metabolized into a compound that is
chemically reactive.1,11Y14 Metabolism may occur in the
liver, where it may not necessarily induce an immune
response, but actual tolerance.15 On the other hand, if a
reactive compound escapes the tolerogenic environment of the
liver or if the immune response to the compound is developed
in lymph nodes outside of the liver (such as probably in severe
drug hypersensitivity syndromes also called drug rash with
eosinophilia and systemic symptoms), a systemic reaction
mainly affecting the skin and with an accompanying hepatitis
may occur.16,17
THE p-i CONCEPT
The hapten and prohapten concept elegantly circum-
vents the (presumed) blindness of the immune system for
lowYmolecular weight compounds by postulating chemical
reactivity and subsequent coupling to a macromolecular
carrier an absolute necessity. As a consequence, drugs and
other substances that are incapable of such conjugation with a
carrier would not be antigens and could not induce hyper-
sensitivity reactions.
We have recently challenged this dogma and proposed a
third model, which is meant to supplement the hapten/
prohapten concept.1,3,18 Termed the p-i concept, which stands
for Bdirect pharmacological interaction of drugs with immune
receptors,[ it states that certain drugs would bind speciﬁcally
and reversibly to some of the highly variable antigen-speciﬁc
receptors in a direct way, instead of covalently modifying the
MHC-peptide complex, which are the 2 feasible Bpartners[ to
accommodate allergy-inducing drugs. Such a drug-TCR
interaction would be metabolism and processing independent
and in fact mimics drug interactions with other nonimmuno-
logic receptors. Although the MHC-peptide complex would
not contribute (much) to the binding energy, it would still be
necessary (1) for full T-cell activation and (2) to direct the
cytotoxic immune response to a target cell. This model has
been elucidated for TCR, but it is possible that BCR on B cells
are activated via a similar mechanism.
Immunologic Data Using Drug-Reactive
T-Cell Clones
This p-i concept was developed over the last 10 years in
our group in Bern and relies on immunologic and clinical
ﬁndings. The generation of drug-reactive (so-called drug-
speciﬁc) T-cell clones (TCCs) allowed better analysis of
drugYT cell interactions and subsequent stimulations. Several
observations argue against processing or covalent binding and
favor the p-i concept.
1. Only some T cells of a patient with drug hypersensitivity
react with the drug. Using TCC, many different chemically
inert drugs were found to be able to stimulate T cells via the
TCR in an MHC-dependent way, in particular, lamotri-
gine,12 carbamazepine,13 sulfamethoxazole (SMX),19 mepi-
vacaine and lidocaine,20 p-phenylenediamine,21 and
ciproﬂoxacin or moxiﬂoxacin.22,23
2. Speciﬁc TCC reacted even if the APCs were ﬁxed by
glutaraldehyde, excluding that either processing or intra-
cellular metabolism is involved.14,19,20
3. Upon pulsing of APCs (incubation of APCs with the
drug for 1 hour followed by 2 washing steps), no stim-
ulation of drug-speciﬁc T-cell clones was observed
for lidocaine, lamotrigine, carbamazepine, ciproﬂoxacin,
and SMX14,19,21,22 as the washing removed the labile
bound drug. Sulfamethoxazole has been characterized
particularly well because the reactive metabolite of
SMX (SMX-nitroso [SMX-NO]) was available for
comparison.24,25 Sulfamethoxazole-nitroso acts as a typi-
cal hapten, capable of covalently modifying the MHC-
peptide complex. This hapten binding results in a very
stable binding, which cannot be washed away and was still
able to stimulate hapten-reactive T cells after washing.19
4. For a number of drugs, the kinetics of T-cell activation are
simply much too fast for any involvement of antigen
processing. In the presence of APCs, lidocaine and SMX
activate T cells quasi immediately, as revealed by a rapid
(within 1 minute) and sustained intracellular Ca2+
increase.19 It is impossible to reconcile this timing with
an intermediate metabolism and processing step, which
needs 60 minutes or longer to occur. In addition, the
kinetics of TCR down-regulation on drug-reactive TCC
after encountering the inert drug are similar to the
recognition of preprocessed immunogenic peptides (occur-
ring within the ﬁrst 30 minutes) and clearly differ from the
recognition of proteins, which requires several hours.19
5. Hypersensitivity to the drug SMX (Fig. 1A) was thought
to be a consequence of bioactivation to the hydroxylamine
metabolite (SMX-NHOH) and further oxidation to the
ultimate reactive metabolite SMX-NO. The antioxidant
glutathione is known to protect cells from reactive meta-
bolites such as SMX-NO by conjugation and subsequent
dissociation to SMX-NHOH and/or SMX.26 Addition of
glutathione to peripheral blood mononuclear cells
enhanced rather than reduced the proliferation to SMX
metabolites, presumably by transforming SMX-NO back
to the Boriginal[ antigen, SMX.26 The response of SMX-
NOYspeciﬁc TCC was abrogated when glutathione was
present during the covalent modiﬁcation of APCs.
Collectively, these experiments support the concept that
TABLE 1. The p-i ConceptVPharmacological Interaction With
Immune Receptors
A chemically inert drug, unable to covalently bind to proteins, is still able to fit
into some of the many immune receptors (as it does into other proteins/
receptors). This reversible drug-receptor interaction can, under certain
circumstances, activate immune cells specific for peptide antigens, which
expand and can cause inflammatory reactions of different types. Such a
reaction would not need the generation of one’s own immune response to the
drug, albeit an expansion of drug-reactive cells may be required before
symptoms appear.
WAO Journal & June 2008 The p-i Concept
* 2008 World Allergy Organization 97
T cells in allergic individuals recognize the noncovalently
bound parent drug SMX rather than APC covalently
modiﬁed by SMX-NO.
6. Drug-speciﬁc TCCs show some peculiar features remi-
niscent of superantigen stimulations but not seen with
classic peptide antigens. Many drug-speciﬁc TCCs were
found to be MHC unrestricted,27 and the frequency of
alloreactivity of the drug-reactive TCC is much higher
among drug- than peptide-speciﬁc TCCs from the same
donor.28 In other words, about 30% of drug-speciﬁc TCCs
did react with an alloantigen without drug.28 The MHC-
bound peptide seems to be irrelevant for SMX-speciﬁc T-
cell activation.29 Lastly, drugs simultaneously elicit a CD4
and CD8 T-cell response to the same compound. These are
features observed with superantigens such as SEB
(staphylococcal euterotoxin B).18
7. The generation of one’s own immune response (often
involving T and B cells) happens with hapten(-carrier)
constructs, but not if the cells are stimulated by the drug
via the p-i concept. In the p-i concept, there is a
remarkable dissociation between T-cell and B-cell
responses: in the better studied T-cell stimulations, often
exclusively T cells react, but no B cells. It is assumed that
no sensitization phaseVas it is typical for an immune
responseVoccurs: if enough cells are able to react with
the drug, symptoms may arise quite rapidly at the ﬁrst
encounter. On the other hand, if only a few T cells react
with the drug, a time interval of a few days may be
observed, similar to an intermittent sensitization phase in
immune responses. Actually, it is assumedVbut not yet
provenVthat the p-iYstimulated T cells are memory T
cells (with an additional peptide speciﬁcity), as the
memory T cells may have a higher readiness to react to
such a minor signal as drug binding to TCR.30 Moreover,
this level of reactivity may be even more reduced by a
concomitant virus infection. This would explain the higher
incidence of drug allergies in systemic virus infections by
herpes viruses or human immunodeﬁciency virus (HIV).
8. In the p-i concept, pharmacology meets immunology. This
raises some semantic problems because each of these 2
areas uses its special words to express its ﬁndings: for
example, in immunology, where only one of million
FIGURE 1. The p-i concept. A schematic representation of the p-i concept in comparison with the hapten concept. A, In the p-i
concept, the drug (eg, SMX) binds to the TCR and provides some initial signal. In most instances, this signal is insufﬁcient to induce
T-cell activation with cytokine synthesis and proliferation. The signal is strengthened by the additional interaction with HLA
molecules. It seems to be rather independent of the type of peptide embedded and sometimes even from the HLA allele. Drug
binding and HLA interactions stimulate T cells like a normal peptide/HLA complex. Because this way of T-cell stimulation does
not follow the rules of the development of a normal immune response, the subsequent activations appear clinically and upon
in vitro analysis often chaotic and uncoordinated. B, In the hapten hypothesis, the hapten-modiﬁed peptide is recognized and
stimulates T cells. The hapten may also have the ability to activate the innate immune system, for example, dendritic cells.
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similar receptors react with a particular antigen, one calls it
recognition of an antigen, whereas in pharmacology, a
basically similar interaction is called ligand binding to its
receptor and not called recognition. Similarly, the term
speciﬁc for an antigen has its particular meaning in
immunology, where afﬁnity maturation is one important
concept and somehow implies an active process. Conse-
quently, one speaks of peptide-speciﬁc T-cell clones and so
on as one particular receptor binds a particular antigen
while another, almost identical, receptor binds to another
antigen. In pharmacology, this enormous polymorphism of
functionally identical receptors is lacking, and normally
only one or a few receptors have one or a few natural
ligands. Is the TCRVspeciﬁc fora certain peptideVwhich
happened to be also stimulated by a drug, now speciﬁc for
the drug, or is the drug binding just an (Baccidental[)
additional interaction? Speciﬁcity seems to be the wrong
term for this pharmacological interaction with an immune
receptor. These semantic problems seem trivial, but can be
a constant reason for misunderstandings.
Immunological Data Using T-Cell
ReceptorYTransfected Hybridoma Cells
To further study these unusual characteristics of drugYT
cell interactions, we recently developed drug-speciﬁc TCR
transfectants. It unequivocally demonstrated that T-cell activa-
tion by drugs is TCR dependent.23,31 Four SMX-speciﬁc, 2
quinolones, and 2 contrast mediaYreactive human TCR were
introduced into the mouse T-cell hybridoma cell line 54X17
(O. Acuto, Paris, France) according to the method described
by Vollmer et al.32 These transfectants expressed drug-speciﬁc
TCR on the cell surface and could be stimulated by the relevant
drug in a speciﬁc way in the presence of APCs, resulting in
interleukin 2 secretion. These TCR-transfected hybridoma cells
behaved like drug-speciﬁc TCC, as the drug could be washed
away (contrary to haptens covalently bound to carrier
molecules), the presence of APC (MHC) was required for
interleukin 2 production, and ﬁxed APC were still able to
present the drug. Similarly, the kinetics of TCR activation were
too fast to involve antigen processing, as antigen-dependent
extracellular signal-regulated kinase (ERK) phosphorylation
was detected within 1 minute of SMX exposure.31 Shufﬂing of
different, SMX- or quinolone-speciﬁc TCR > or A chains
revealed that recognition depends on the coordinated expression
of both original TCR chains to keep reactivity to the drugs.23
A further support for the p-i concept comes from the
recent elegant study by Chen’s group from Taiwan.33,34 After
having demonstrated the high association of Stevens-Johnson
syndrome to HLA-B*1502 in Han Chinese, they eluted the
peptides from HLA-B*1502Ypositive cell lines incubated with
carbamazepine. The eluated peptides did not contain any
covalently bound carbamazepine, and the authors conclude that
their data would support the p-i concept.34
The p-i Concept: Bypassing the Innate Immune
System Because of Cross-Reactivity
With Peptide Antigens
The p-i concept has major implications for our inter-
pretation of drug-induced immune-mediated side effects. It
actually puts some drug-induced hypersensitivity reactions
outside the rules for a normal immune response.35 This could
explain some peculiar clinical ﬁndings, namely that drug-
induced T cellYmediated skin reactions can occur already
within a few hours after administration and/or without previous
exposure to the drug, as for example, documented for radio-
contrast media.36 The kinetics of such a reaction are much too
fast to be explained by the induction of a classic primary
response, which is mounted in the course of several days only.
To explain these phenomena, we proposed that the drugs
are bypassing the innate immune system as they stimulate
memory T cells (with a peptide speciﬁcity).30 Such memory T
cells have a lower threshold of reactivity compared with naive
T cells, which might even be further decreased if a generalized
immune reaction with its abundance of cytokines is occurring.
A secondary memory response by the immune system is gen-
erallymuch faster and can lead to an immune reactionwithin the
time frame observed for some adverse drug reactions. More-
over, these features would explain the higher incidence of drug
hypersensitivity reactions during such infections or auto-
immune diseases. It implies that drug hypersensitivity reac-
tions are actually caused by cross-reactivity of peptide-speciﬁc
memory T cells, which happen to react also with some drugs.
In line with this notion is the observation that most drug-
speciﬁc TCCs have been found to bear >A TCRs, which usually
recognize peptides, and that a general stimulation of T cells as in
HIV or Epstein-Barr virus, cytomegalovirus infection, or
exacerbation of autoimmune diseases is an important risk factor
for drug hypersensitivity.37 On the other hand, recent data
suggest that the drug-induced T-cell activation leads to a
reactivation of dormant herpes viruses and that the later
appearing symptoms during drug hypersensitivity syndromes/
drug rash with eosinophilia and systemic symptoms are largely
related to reactivated herpes virus infections.38 The incidence of
SMXallergy in healthy subjects is ca. 2% to 4%, but duringHIV
infection, it might go up to ca. 50%, and amoxicillin
hypersensitivity increases from 4% to 5% in healthy subjects
to greater than 90%during an acute Epstein-Barr virus infection
(infectious mononucleosis). Such immune reactions go along
with the expansion of a polyclonal CD8+ T-cell response, and
such T cells are also found in the circulation of patients with
maculopapular and bullous exanthema.39 Even more, it seems
likely that drug-speciﬁc cells exist even in individuals who are
not hypersensitive. In an invitro study, several blood donorswho
had never been exposed to SMX nevertheless harbored SMX-
and SMX-NOYspeciﬁc cells in their T-cell repertoire.40
Clinical Data and Preferential Involvement
of the Skin
Although the immune response to proteins, bacteria, viru-
ses, and so on is well coordinated and localized to the affected
organ, the immune response to a drug is often uncoordinated and
generalized. It somehow circumvents the checkpoints for
immune activation imposed by the classic antigen processing
and presentation mechanisms, which may help to explain some
of the peculiar pictures of drug hypersensitivity reactions such as:
a) the uncoordinated nature of drug allergic systemic
reactions, which involve Th1, Th2, and CXCL-
8Ysecreting T cells simultaneously;
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b) the rapid appearance after the ﬁrst encounter with the
drug, without any sensitization phase;
c) some drugs causing delayed hypersensitivity reactions
are not known to be metabolized to a chemically reactive
compound; and
d) many chemically inert drugs, unable to form hapten-
carrier complexes in the skin, are nevertheless able to
cause positive skin tests with lymphocyte inﬁltra-
tion.39,41 It is difﬁcult to imagine that the locally applied
drug in epicutaneous patch tests is transported to the
liver, there metabolized and returns to the skin to cause a
local reaction there.
Indeed, the p-i concept may better explain the general-
ized appearing skin symptoms than the hapten concept.42 The
p-i concept takes into account that drugs are ubiquitously
distributed in the body, the lack of potent metabolism in the
skin and the well-described sentinel function of some resident
T cells in the skin.43 Oral or parenteral uptake of drugs leads
rapidly to a distribution throughout the body. This is
particularly well documented for the skin, where for example,
an antihistamine given orally can reach tissue levels within 45
to 60 minutes, which can block H1 receptors completely. This
rapid distribution throughout the body may not only allow an
interaction with an appropriate receptor but also with TCRs on
certain T cells (p-i concept). Interestingly, the skin contains an
extremely dense network of sentinel preactivated T cells
(ready to react rapidly to an eventual Bintruder[) in close
apposition to dendritic cells, which may predestine the skin to
be the most frequently involved organ in drug hypersensitivity
(based on the p-i concept). Such an environment provides ideal
conditions for T-cell stimulation according to the p-i concept.
Probably, these sentinel T cells may have a lower threshold of
activation then naive T cells or circulating T cells because they
are already preactivated.43
The p-i Concept and HLA Restriction in Drug
Hypersensitivity
The p-i concept is not conceived as opposing the hapten
or prohapten concept, but supplementing it. Certain drugs
such as penicillins may cause hypersensitivity reactions
caused by hapten-carrier formation. Others, such as quino-
lones and sulfanilamides, may cause hypersensitivity by the
hapten and p-i concept simultaneously.4,22,24 Thus, if the
hapten concept is well proven for a certain drug such as p-
phenylenediamine or SMX, it does not rule out that the p-i
concept is not also playing some role.
The p-i concept is contradicting many well-established
rules in immunology. However, this is no argument against it
as it is no more immunology but pharmacology; and the
ﬁndings in drug allergy do contradict many established
rules.35 Actually, the fact that the p-i concept is not implying
an immune response to a drug may explain many of these
puzzling ﬁndings. Drug hypersensitivity generated according
to the p-i concept is not caused by a newly generated immune
response to the drug but is the consequence of cross-reactivity.
It does not require the involvement of the innate immune
system to trigger immunity. Animal experiments aimed to
prove or disprove the p-i concept by immunizing animals with
the inert drug will necessarily failVas inert drugs do not
stimulate an immune response under normal conditions.44
Actually, the p-i concept cannot be proven by usual
immunologic tests but is better accessible to pharmacology
of the TCR-drug interactions.
In the p-i concept, drugs are thought to primarily activate
the TCR. How can one reconcile this concept with the striking
HLA-B associations described for certain severe drug
hypersensitivity reactions? Indeed, some of the most convin-
cing HLA associations of disease were recently described for
severe, often bullous, drug hypersensitivity reactions. For
example, the abacavir-induced severe hypersensitivity reaction
affecting multiple organs is strongly associated with the HLA-
B*5701 allele in whites,45 the Stevens-Johnson syndrome
after carbamazepine treatment in Han Chinese occurs in
patients with the HLA-B*1502 allele,33 and HLA-B*5801 is
an important genetic risk factor for severe allopurinol-induced
cutaneous adverse reactions such as Stevens-Johnson syn-
drome and toxic epidermal necrolysis.46 It is clear that such
strong associations with HLA alleles support an important role
for HLA molecules in drug hypersensitivity. The HLA
associations are usually explained by the presentation of
certain peptides by a certain HLA allele. The hypothesis would
be that certain peptides, presented rather exclusively by these
HLA molecules, present the bound hapten in a particularly
immunogenic form. However, albeit the association with HLA
alleles is very strong, there are some open questions. Many
patients with HLA-B*5801 are exposed to allopurinol, yet
FIGURE 2. HLA-allele association and p-i concept. Some drugs
elicit severe, often CD8-dominated, immune reactions in
patients with a certain HLA-B alleles (carbamazepine and
HLA-B*1502, allopurinol with HLA-B*5801, abacavir with
HLA-B*5701). If these drugs stimulate via the p-i concept
(as well documented for carbamazepine [CBZ], but not
abacavir or allopurinol), then the strong HLA association would
be explained by the ability of only the selected HLA allele to
supplement the activation caused by the respective drug. In the
example given, the HLA alleles B*0701 or B*2701 would be
unable to supplement this initial signal by CBZ. However, none
of the existing hypotheses can explain the ﬁnding that some of
these alleles are found to be involved only in certain human
races (eg, CBZ and HLA-B*1502 in Han Chinese). SJS indicates
Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
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they do not develop hypersensitivity.46 Whites do not show the
association of HLA-B*1502 and carbamazepine hypersensi-
tivity,47 and most TCCs to carbamazepine generated from
whites reacted with the parent compound.13 Also and as
reported by the authors of these studies, other factors located
in this region of chromosome 6 may be important as well (eg,
HSP 70 and other genes).45,48 Lastly, until now, no particular
peptide or hapten-modiﬁed peptide could be identiﬁed and
eluted from the HLA-B alleles.33
Thus, one could propose an alternative possibility. In the
p-i concept, the drug binds primarily to a certain TCR.
However, this binding needs supplementing interaction with
an HLA molecule, which can only be given by a certain HLA-
B allele. In the absence of this HLA-B allele, the drugs cannot
stimulate sufﬁciently (Fig. 2).
CONCLUSIONS
A series of clinical and laboratory investigations contra-
dict the hapten model and suggest that the hapten model as the
sole molecular explanation for drug-induced hypersensitivity
may not be sufﬁcient. We recently proposed the p-i concept,
which supplements the hapten concept. In this concept, certain
drugs are considered to be able to activate T cells by binding to
T-cell receptors and subsequent cell activation. This explains
many of the peculiar ﬁndings in drug hypersensitivity and opens
new possibilities for immunopharmacology, as this drug
binding may be stimulatory or inhibitory.
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